Methods and Results Three groups of 12 dogs each were studied at baseline and during 2 to 6 hours of coronary artery occlusion and 15 minutes of reperfusion. In group 1 dogs, which did not receive dobutamine during any of these stages, percent wall thickening at these stages was 32+6%, -2±6%, and 5 ±6%, respectively, and there was no relation between infarct size and percent wall thickening during reflow (r=.20, P=.51). In group 2 dogs, which received 15 ,ug/kg per minute of dobutamine at all stages, wall thickening at these stages was 40±8%, 0±8%, and 19±10%, respectively, and a good inverse correlation was noted between infarct size and percent wall thickening during reflow (r= -.81, P=.001). In group 3 dogs, in which wall thickening during reflow was measured both before and during infusion of 15 ,ug/kg per minute of dobutamine, it was 5±8% and 18±14%, respectively, at these stages. Although the correlation between infarct size and percent wall thickening was poor in the absence of dobutamine (r=.36, P=.26), an excellent inverse correlation was noted between the two in the presence of dobutamine (r= -.93, P<.001). A fair inverse correlation was also noted between infarct size and the absolute change in wall thickening induced by dobutamine (r= -.72, P<.01). Maximal wall thickening was noted at a dobutamine dose of 15 ,ug/kg per minute, and lower doses did not elicit thickening in the presence of larger infarcts despite the presence of viable myocardium.
Conclusions When myocardial necrosis coexists with postischemic myocardial dysfunction and no residual coronary stenosis, the absolute degree of wall thickening during dobutamine can be used to determine the extent of myocardium that has escaped necrosis. The dose of dobutamine needed to elicit maximal thickening of the postischemic myocardium is related to the amount of myocardial necrosis. (Circulation. 1994; 90:1502 -1512 Key Words * echocardiography * myocardium a reperfusion A ssessment of regional left ventricular (LV) function provides important insights in patients with coronary artery disease. For example, LV wall thickening at rest is abolished after a myocardial infarction involving a substantial portion of the myocardial thickness.1 In contrast, if the myocardium escapes necrosis as a consequence of timely reperfusion, recovery in function of the postischemic myocardium occurs, which is related to the severity and duration of myocardial ischemia. 2, 3 Unlike pure postischemic myocardial dysfunction without associated myocardial necrosis described in animal models,23 in the clinical setting-where thrombolytic therapy or mechanical intervention is used -it is rare to see postischemic myocardium without some ©0 1994 American Heart Association, Inc. degree of associated myocardial necrosis. Moreover, since it may take days to weeks for functional recovery of the postischemic myocardium to occur,4-6 assessment of regional LV function immediately after reperfusion does not indicate the extent of myocardial salvage that has been achieved. Since the endocardial half of the left ventricle is the major contributor toward wall thickening,7-10 regional function may not improve if a substantial portion of the endocardium is necrosed despite salvage of the remaining myocardium. 1 Because postischemic myocardium has contractile reserve,2,3 we hypothesized that infusion of an inotropic agent such as dobutamine would increase thickening of the salvaged viable myocardium and that the absolute degree of thickening induced by dobutamine would be directly related to the amount of myocardium that has escaped necrosis. Our hypothesis would imply that in the presence of endocardial necrosis, the epicardial half of the myocardium -which under baseline condition does not thicken much7 8- In the group 2 dogs, risk area was defined using technetium autoradiography.13-15 Twenty millicuries of technetium-99m (Cardiolite, DuPont) was injected into the left atrium toward the end of the occlusion period. At the conclusion of the experiment, a short-axis slice corresponding to the plane of the two-dimensional echocardiographic image was cut from the excised heart. The slice was placed on double-emulsion x-ray film (X-Omatic AR, Eastman Kodak), which was exposed for 14 to 18 hours and developed using an automatic developer (model M35A, X-Omatic, Eastman Kodak). A back-illuminated image of the autoradiograph was captured into the off-line computer using a video camera (66 series, Dage-MTI Corp). The risk areadefined as the transmural defect on the autoradiograph-was planimetered and expressed as a percent of the myocardium in the short-axis slice. It also was drawn on a plastic overlay for determining the region where wall thickening analysis was performed in the group 2 dogs.
Determination of Infarct Size
The heart slice corresponding to the two-dimensional echocardiographic image was immersed in a solution of 1 sis not only for longer periods (>3 hours) of coronary occlusion and reperfusion17 but also for shorter periods (90 to 240 minutes of coronary occlusion and 5 minutes of reperfusion).18 An image of the stained slice was captured into the off-line computer using the video camera, and the infarct was measured and expressed as a percent of the myocardial slice.
Experimental Protocol
After hemodynamic and two-dimensional echocardiographic data at baseline were acquired (without dobutamine in group 1 and 3 dogs and in the presence of 15 ,ug/kg per minute of dobutamine in group 2 dogs), 100 mg of lidocaine hydrochloride (Abbott Laboratories) was given intravenously in group 1 and 2 dogs followed by a 2 mg/min constant infusion; group 3 dogs did not receive any lidocaine. The proximal portions or midportions of the LAD or LCx were occluded for 2 to 6 hours to cause infarctions of varying sizes. Normal saline, phenylephrine, and sodium bicarbonate were given as needed to maintain hemodynamic and metabolic status within the physiological range during coronary occlusion in the group 1 and 2 dogs; no drugs were used in group 3 dogs to avoid the influence of any drug on either wall thickening or infarct size.
Toward the end of the occlusion period, wall thickening was measured using two-dimensional echocardiography in all dogs; risk area was determined using myocardial contrast twodimensional echocardiography in the group 1 and 3 dogs and using technetium autoradiography in the group 2 dogs. The occlusion was then released, and after 15 minutes of reperfusion, two-dimensional echocardiography was again performed to measure wall thickening in the absence of dobutamine in group 1 dogs, in the presence of dobutamine in group 2 dogs, and both before and during infusion of dobutamine in group 3 dogs. In addition, in 3 group 1 and 3 group 2 dogs, at the end of the experiment, dobutamine was given for 3 minutes each in doses of 5, 10, 15, and 20 pg/kg per minute to determine the optimal dose for eliciting maximal thickening in the postischemic myocardium with varying degrees of coexistent myocardial necrosis. The dogs were then killed by pentobarbital overdose, the heart was excised, and the slice corresponding to the two-dimensional echocardiographic image was processed to determine risk area by technetium autoradiography in the group 2 dogs and infarct size in all three groups of dogs.
Statistical Analysis
Data were analyzed using RS1 (Bolt, Beranek, and Newman) resident on a VAX4000 computer system (Digital Equipment Corp) and were expressed as mean± 1 SD. Comparisons between wall thickening and infarct size were made using linear regression analysis. Comparisons between stages were made using one-way ANOVA. Statistical significance was defined as P<.05 (two-sided).
Results
Three group 1 and 2 group 2 dogs required phenylephrine to maintain a systolic blood pressure of >90 mm Hg during coronary occlusion. Two group 1 and 1 each of group 2 and group 3 dogs required defibrillation in the first 30 minutes of coronary occlusion.
Hemodynamic Data
Hemodynamic data of all three groups of dogs are depicted in Table 1 . In the group 1 dogs, which did not receive dobutamine, there were no significant differences in the aortic pressures during baseline, coronary occlusion, and reperfusion (Table 1) . Although the left atrial pressure increased during occlusion, it did not differ significantly from baseline and reperfusion. In group 2 dogs, all pressures were measured in the presence of 15 ,ug/kg per minute of dobutamine (Table  1) . Like the group 1 dogs, this group also did not show any statistical differences in aortic and left atrial pressures during any of the stages. Likewise, in group 3 dogs, there were also no significant differences in the aortic and left atrial pressures during the different stages in the absence of dobutamine (Table 1) . After 15 pg/kg per minute of dobutamine was infused during reflow, although aortic pressures tended to be higher, no significant differences were noted compared with other stages because of a large variability in the blood pressure response to dobutamine (Table 1 ). There were no differences between the hemodynamics of group 2 and 3 dogs during reflow in the presence of dobutamine. Unlike the group 1 dogs (Fig 3A) , there was a close inverse relation between infarct size, expressed as a percent of risk area, and wall thickening in the group 2 dogs (Fig 3B) thickening would be noted in the postischemic myocardium in the absence of infarction, whereas a total transmural infarction would result in no thickening despite using moderate doses of dobutamine.
As depicted in Fig 6B, an inverse relation was also noted in the group 3 dogs between infarct size, expressed as a percent of risk area, and the change in wall thickening induced by 15 gg/kg per minute of dobutamine: y= -0.27x+22.0 (r= -.72, P<.01, SEE= 8.7). Unlike absolute wall thickening, however, change in thickening had more scatter, particularly when the infarction was small, which was related to a large variability in postischemic wall thickening noted in the absence of any infarction (Fig 6A) . Based on the data depicted in Fig 6B, Our study demonstrates that at a dose of 15 ,g/kg per minute and in the absence of a flow-limiting coronary stenosis supplying the postischemic myocardium, the degree of thickening of this myocardium is inversely related to the extent of necrosis present. This finding indicates that stimulation of the myocardium after successful reperfusion could provide an indirect estimation not only of the presence but also the amount of viable myocardium. Unlike the absolute degree of myocardial thickening, the change in wall thickening in the presence of 15 ,g/kg per minute of dobutamine was not as predictive of the extent of myocardial viability. This phenomenon is probably related to the large variability in wall thickening noted in the postischemic myocardium even in the absence of necrosis, which may be related to loading conditions, myocardial blood flow, and other undefined causes. This variability in thickening noted in the absence of dobutamine is no longer seen in the presence of 15 gg/kg per minute of dobutamine, where the contractile reserve is directly related to the extent of salvaged myocardium. These results indicate that measurement of absolute wall thickening Dobutamine two-dimensional echocardiography is being used increasingly in the clinical setting for determining the presence of viable myocardium.30-33 To our knowledge, there have been no controlled experimental studies defining the physiological basis of using dobutamine two-dimensional echocardiography for this purpose. The results from our study form a framework based on which previous and future clinical observations using this technique can be interpreted.
It may be important to know the coronary anatomy before interpreting results of dobutamine two-dimen-sional echocardiography in patients who have received thrombolysis. For instance, wall thickening may not increase in the presence of dobutamine either because there is very little viable myocardium or else a critical residual stenosis is still present despite substantial amounts of viable myocardium. Obviously, the implications of these two situations are different.
The dose of dobutamine required to elicit the maximal contractile reserve may be higher than the low-dose dobutamine used currently in clinical practice.31,32 Lowdose dobutamine may significantly underestimate the extent of viable myocardium. That myocardial response to this dose has been shown to correlate with ultimate recovery in regional function in some patients31,32 may simply be because spontaneous recovery in regional function is more likely to occur in those with the least amount of necrosis, and these patients are likely to respond to even low doses of dobutamine. Others with more necrosis but with significant amounts of viable myocardium who are not likely to demonstrate spontaneous recovery in regional function could be missed using these doses; consequently, higher doses would be required to elicit viable myocardium in these patients. Greater knowledge of the coronary anatomy could also make it easier to use larger doses safely in patients with mild residual stenosis.
In patients with noncritical residual stenosis who do not demonstrate spontaneous recovery in regional function, the myocardial response to dobutamine could be used to predict the long-term benefits of reperfusion therapy. Although speculative at this juncture, this aspect of dobutamine two-dimensional echocardiography may provide insights that are not readily available using other means. For instance, Pierard and colleagues33 noted viability on positron emission tomography in 11 of 17 patients with anterior myocardial infarction who had undergone successful thrombolysis within 3 hours of the onset of symptoms. Although all 11
showed improvement in function with 10 jig/kg per minute of dobutamine, only 6 showed spontaneous recovery later. Thus, dobutamine two-dimensional echocardiography at a moderate dose identified more viable myocardium than would have been predicted on the basis of spontaneous recovery in regional function. It is also likely that the 5 patients with viable myocardium who did not demonstrate spontaneous recovery in regional function but who showed enhanced regional function with dobutamine had enough normal myocardium to buttress the infarct tissue, thus preventing infarct expansion and heart failure. 4 To address these and other issues, further studies are required to establish the role of dobutamine two-dimensional echocardiography in patients with postischemic myocardial dysfunction.
